175 related articles for article (PubMed ID: 32387182)
21. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
Yokooji T; Kawabe Y; Mori N; Murakami T
J Pharm Pharmacol; 2013 Feb; 65(2):280-91. PubMed ID: 23278696
[TBL] [Abstract][Full Text] [Related]
22. The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice.
Wang Y; Sun L; Chen S; Guo S; Yue T; Hou Q; Feng M; Xu H; Liu Y; Wang P; Pan Y
Life Sci; 2019 Aug; 231():116529. PubMed ID: 31173781
[TBL] [Abstract][Full Text] [Related]
23. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Fujita D; Saito Y; Nakanishi T; Tamai I
Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetics of irinotecan disposition and toxicity: a review.
Fujita K; Sparreboom A
Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
[TBL] [Abstract][Full Text] [Related]
25. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
Iyer L; Ramírez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
[TBL] [Abstract][Full Text] [Related]
26. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
Gupta E; Wang X; Ramirez J; Ratain MJ
Cancer Chemother Pharmacol; 1997; 39(5):440-4. PubMed ID: 9054958
[TBL] [Abstract][Full Text] [Related]
27. Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.
Kato A; Ueyama J; Abe F; Hotta K; Tsukiyama I; Oshima T; Kondo F; Saito H; Hasegawa T
Anticancer Res; 2011 Sep; 31(9):2915-22. PubMed ID: 21868538
[TBL] [Abstract][Full Text] [Related]
28. Role of MRPs transporters in pharmacokinetics and intestinal toxicity of irinotecan.
Du T; Luo T; Wang J; Sun R; Cai H
Food Chem Toxicol; 2023 Dec; 182():114171. PubMed ID: 37956707
[TBL] [Abstract][Full Text] [Related]
29. PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity.
Fontaine SD; Santi AD; Reid R; Smith PC; Ashley GW; Santi DV
Cancer Chemother Pharmacol; 2020 Jan; 85(1):225-229. PubMed ID: 31707444
[TBL] [Abstract][Full Text] [Related]
30. Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities.
Wang SW; Kulkarni KH; Tang L; Wang JR; Yin T; Daidoji T; Yokota H; Hu M
J Pharmacol Exp Ther; 2009 Jun; 329(3):1023-31. PubMed ID: 19264971
[TBL] [Abstract][Full Text] [Related]
31. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
Cancer Chemother Pharmacol; 2000; 46(3):211-20. PubMed ID: 11021738
[TBL] [Abstract][Full Text] [Related]
32. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
33. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
34. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
35. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
[TBL] [Abstract][Full Text] [Related]
36. Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation.
Parvez MM; Basit A; Jariwala PB; Gáborik Z; Kis E; Heyward S; Redinbo MR; Prasad B
Drug Metab Dispos; 2021 Aug; 49(8):683-693. PubMed ID: 34074730
[TBL] [Abstract][Full Text] [Related]
37. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
[TBL] [Abstract][Full Text] [Related]
38. Effects of inflammation on irinotecan pharmacokinetics and development of a best-fit PK model.
Chityala PK; Wu L; Chow DS; Ghose R
Chem Biol Interact; 2020 Jan; 316():108933. PubMed ID: 31870839
[TBL] [Abstract][Full Text] [Related]
39. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Nagar S; Blanchard RL
Drug Metab Rev; 2006; 38(3):393-409. PubMed ID: 16877259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]